Novo Nordisk Raises 2026 Outlook on Strong Wegovy® Pill Launch and Initiates DKK 11.2B Share Buyback Tranche

summarizeSummary

Novo Nordisk reported Q1 2026 results, raising its full-year 2026 adjusted sales and operating profit guidance due to strong Wegovy® product performance, and initiated a new DKK 11.2 billion share repurchase tranche.

check_boxKey Events

• Q1 2026 Financial Performance

  Reported sales increased by 32% at constant exchange rates (CER) to DKK 96,823 million, and reported operating profit increased by 65% at CER to DKK 59,618 million, significantly impacted by a USD 4.2 billion (DKK 26.8 billion) 340B provision reversal. Adjusted sales (excluding the reversal) decreased by 4% at CER to DKK 70,063 million, and adjusted operating profit decreased by 6% at CER to DKK 32,858 million.

• Raised 2026 Financial Outlook

  The company raised its full-year 2026 guidance for adjusted sales growth at CER from -5% to -13% to -4% to -12%. Adjusted operating profit growth at CER was also raised from -5% to -13% to -4% to -12%. Free cash flow guidance was increased from DKK 35-45 billion to DKK 36-46 billion.

• Strong Wegovy® Product Performance

  Wegovy® pill, launched in the US on January 5, 2026, recorded over 2 million total prescriptions since launch and Q1 sales of DKK 2,256 million. Wegovy® HD (injectable semaglutide 7.2 mg) was approved by the FDA in March and launched in the US on April 7, demonstrating 20.7% mean weight loss in trials.

• New Share Repurchase Tranche Initiated

  Novo Nordisk initiated a new share repurchase program for up to DKK 11.2 billion (approximately $1.6 billion USD), effective May 6, 2026, as part of its overall DKK 15 billion program for 2026. The company has already repurchased DKK 3.8 billion of shares as of May 4, 2026.

auto_awesomeAnalysis

Novo Nordisk reported mixed Q1 2026 financial results, with reported sales and operating profit significantly boosted by a non-recurring USD 4.2 billion 340B provision reversal. Excluding this, adjusted sales and operating profit declined year-over-year. However, the company raised its full-year 2026 guidance for adjusted sales and operating profit, driven by increased expectations for GLP-1 product sales. The strong commercial performance of Wegovy® pill, which achieved over 2 million prescriptions since its January launch, and the approval and launch of Wegovy® HD, are key drivers. Additionally, Novo Nordisk initiated a new DKK 11.2 billion tranche of its share repurchase program, demonstrating a commitment to returning capital to shareholders. Investors should note the announced list price reductions for Wegovy® and Ozempic® effective January 2027, which will impact future cash flow.